EUCALIA Inc
TSE:286A

Watchlist Manager
EUCALIA Inc Logo
EUCALIA Inc
TSE:286A
Watchlist
Price: 914 JPY 0.99%
Market Cap: ¥34.7B

EUCALIA Inc
Note Receivable

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

EUCALIA Inc
Note Receivable Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Note Receivable CAGR 3Y CAGR 5Y CAGR 10Y
EUCALIA Inc
TSE:286A
Note Receivable
¥364.3m
CAGR 3-Years
-27%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
E
Elan Corp
TSE:6099
Note Receivable
¥950.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Solasto Corp
TSE:6197
Note Receivable
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
BML Inc
TSE:4694
Note Receivable
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
H.U. Group Holdings Inc
TSE:4544
Note Receivable
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
France Bed Holdings Co Ltd
TSE:7840
Note Receivable
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

EUCALIA Inc
Glance View

Market Cap
34.7B JPY
Industry
Health Care

EUCALIA, Inc. engages in the elderly care, hospital management and operations, and medical tourism businesses. The company is headquartered in Chiyoda-Ku, Tokyo-To and currently employs 833 full-time employees. The company went IPO on 2024-12-12. The company operates through three segments. The Medical Management Comprehensive Support Business segment provides comprehensive support for issues faced by affiliated medical corporations, including management consulting, personnel recruitment support, digital transformation (DX) support, and fundraising support. The Senior Related Business segment provides nursing care services such as the operation of nursing care facilities, as well as consultation on admission to nursing care facilities and facility introduction services. The Highly Controlled Medical Device Business segment manufactures and sells contact lenses. The company also provides treatment progress data analysis and sales activity support services for pharmaceutical companies. Through its subsidiaries, it is also engaged in venture investment, as well as the provision of brain checkup services, and real estate buying and selling services.

286A Intrinsic Value
851.66 JPY
Overvaluation 7%
Intrinsic Value
Price ¥914

See Also

What is EUCALIA Inc's Note Receivable?
Note Receivable
364.3m JPY

Based on the financial report for Dec 31, 2025, EUCALIA Inc's Note Receivable amounts to 364.3m JPY.

What is EUCALIA Inc's Note Receivable growth rate?
Note Receivable CAGR 3Y
-27%

Over the last year, the Note Receivable growth was -2%. The average annual Note Receivable growth rates for EUCALIA Inc have been -27% over the past three years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett